Last reviewed · How we verify
SNP-ACTH (1-39) Gel
SNP-ACTH (1-39) Gel is a synthetic peptide that mimics the action of adrenocorticotropic hormone (ACTH) to stimulate the production of cortisol.
SNP-ACTH (1-39) Gel is a synthetic peptide that mimics the action of adrenocorticotropic hormone (ACTH) to stimulate the production of cortisol. Used for Congenital adrenal hyperplasia.
At a glance
| Generic name | SNP-ACTH (1-39) Gel |
|---|---|
| Sponsor | Cerium Pharmaceuticals, Inc. |
| Drug class | corticosteroid |
| Target | melanocortin receptors |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
SNP-ACTH (1-39) Gel works by binding to melanocortin receptors in the skin, which leads to increased production of cortisol. This increase in cortisol production can help to improve symptoms of adrenal insufficiency. The exact mechanism of action is not fully understood, but it is thought to be related to the stimulation of melanocortin receptors.
Approved indications
- Congenital adrenal hyperplasia
Common side effects
- Skin irritation
- Hypertension
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNP-ACTH (1-39) Gel CI brief — competitive landscape report
- SNP-ACTH (1-39) Gel updates RSS · CI watch RSS
- Cerium Pharmaceuticals, Inc. portfolio CI